EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex:AIS) today announced that the Company has received an $875,000 milestone payment from Bradley Pharmaceuticals Inc. (NYSE:BDY) pursuant to a marketing agreement Bradley signed with Biosante Pharmaceuticals (Amex:BPA) for Bio-E-Gel® (transdermal estradiol gel). Additional regulatory and sales based milestone payments could bring the total of such payments to Antares to more than $13 million. Pending approval by the U.S. Food and Drug Administration(FDA), Antares will receive an important portion of the royalties on third party sales of Bio-E-Gel® as well.
